The agency’s announcement promises to alleviate a year-and-a-half-long backlog of exclusivity determinations, but legislation is needed to prevent future litigation from paralyzing the system again.
MM+M Podcast 6.14.22: Why Europe wants to close the orphan drug loophole
Preferential treatment for orphan drugs is very much in play overseas. Jack Mycka, VP in the PRMA division of Indegene, explains what potential European reforms could mean for pharma marketers.
Orphan drugs to grow twice as fast as rest of the industry: report
By allowing companies to claim a 50% tax credit for qualified clinical testing expenses, developing drugs for rare diseases became economically feasible for the first time.
Five things for pharma marketers to know: Wednesday, January 3, 2018
Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark’s genetic therapy for rare blindness costs $850,000
Top 25 rare disease brands, by sales
February 15, 2017
3:35 pm
Teva Pharmaceutical Industries’ Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
Five things for pharma marketers to know: Thursday, September 8, 2016